Earnings | Divis Laboratories Ltd (NSE: DIVISLAB): Q4FY23 Results Out; Total Income fell 21% YoY.

Divis Laboratories Ltd is a renowned Indian company specializing in the production and global export of Active Pharmaceutical Ingredients (APIs), Intermediates, and Nutraceutical ingredients. With a solid reputation in the pharmaceutical industry, the company has established itself as a leading manufacturer of high-quality chemicals. Divis Laboratories focuses on research, development, and manufacturing processes, adhering to strict quality standards to meet global regulatory requirements. Its API portfolio spans various therapeutic categories, serving the pharmaceutical industry’s diverse needs. In addition, the company also offers a range of intermediates and nutraceutical ingredients. Divis Laboratories’ commitment to excellence and its robust product portfolio contribute to its position as a trusted and reliable supplier in the global market.
• Divis Laboratories Ltd reported Total Income for Q4 FY23 of ₹2,017 Crore down from ₹2,571 Crore year on year, a negative growth of 21%.
• Total Expenses for Q4 FY23 of ₹1,550 Crore up from ₹1,495 Crore year on year, a growth of 3%.
• Consolidated Net Profit of ₹ 321 Crore, down 64% from ₹894 Crore in the same quarter of the previous year.
• The Earnings per Share is ₹12.09, down 64% from ₹33.70 in the same quarter of the previous year.